2.57
-0.05(-1.91%)
Currency In USD
| Previous Close | 2.62 |
| Open | 2.62 |
| Day High | 2.66 |
| Day Low | 2.56 |
| 52-Week High | 6.5 |
| 52-Week Low | 2.37 |
| Volume | 118,060 |
| Average Volume | 336,330 |
| Market Cap | 138.66M |
| PE | -1.4 |
| EPS | -1.83 |
| Moving Average 50 Days | 2.83 |
| Moving Average 200 Days | 3.8 |
| Change | -0.05 |
If you invested $1000 in Orchestra BioMed Holdings, Inc. (OBIO) since IPO date, it would be worth $225.44 as of September 13, 2025 at a share price of $2.57. Whereas If you bought $1000 worth of Orchestra BioMed Holdings, Inc. (OBIO) shares 3 years ago, it would be worth $260.15 as of September 13, 2025 at a share price of $2.57.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout
GlobeNewswire Inc.
Sep 04, 2025 9:00 PM GMT
Results from long-term follow up of patients treated with atrioventricular interval modulation (“AVIM”) therapy show blood pressure-lowering effects are sustained for years after activation, reversible with no observed rebound hypertension upon deact
Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology
GlobeNewswire Inc.
Aug 26, 2025 11:30 AM GMT
Data from acute and chronic pressure-volume loop studies support the mechanism of action and show a favorable impact of AVIM therapy on blood pressure and cardiovascular hemodynamicsAVIM therapy drove statistically significant reductions in systolic
Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction
GlobeNewswire Inc.
Aug 14, 2025 12:00 PM GMT
Echocardiographic data analysis demonstrated favorable impact of atrioventricular interval modulation (“AVIM”) therapy on MODERATO II study patients with diastolic dysfunction, a key component in the development of heart failure with preserved ejecti